Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GEO-MM01
- Development stage
- Preclinical
- Lead developer
- GeoVax Labs
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular (preclinical Studies)
01
Overview
GEO-MM01 is a preclinical vaccine candidate developed by GeoVax Labs for the prevention of Marburg virus disease. It utilizes a Modified Vaccinia Ankara (MVA) viral vector platform to express Marburg virus antigens, aiming to induce both humoral and cellular immune responses. In nonhuman primate studies, immunization with GEO-MM01 resulted in 80% survival following exposure to a lethal dose of Marburg virus, with protection against viremia, weight loss, and mortality. The vaccine elicited neutralizing antibodies as well as functional T cell responses. Earlier studies in guinea pigs showed 100% protection against death from the Angola strain of Marburg virus[2][3][6]. The candidate is currently in the exploratory/preclinical stage.
- Other names
- GeoVax Marburg vaccineMVA-MARV VLP vaccine
Beyond the preview
Go deeper on GEO-MM01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GEO-MM01.